{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:52:17Z","timestamp":1776880337961,"version":"3.51.2"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n Patients with papillary thyroid carcinoma (PTC) with lateral neck metastases (N1b) are usually treated with total thyroidectomy (TT), neck dissection, and adjuvant radioactive iodine (RAI). This philosophy comes with higher risks of complications and sequela than thyroid lobectomy (TL) and neck dissection alone. There are no prior studies on patients from the Western hemisphere that compare survival and recurrence outcomes between these groups.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare recurrence and survival outcomes in propensity-matched TL vs TT + RAI patients who presented with ipsilateral N1b PTC at a tertiary cancer center in the US.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort propensity-matched study was conducted at a single US tertiary cancer center included 37 TL patients and 37 of 561 TT + RAI patients (after excluding patients with M1 disease), with a median (IQR) follow-up of 113 (58-241) and 90 (48-185) months, respectively. Adult patients with PTC with lateral neck node metastases (N1b) were identified from a thyroid cancer database. The study included patients undergoing surgery at Memorial Sloan Kettering Cancer Center from 1986 to 2020, inclusive, and the study was conducted from 2024 to 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 598 total individuals, the median (IQR) age was 41 (33-55) years, and 341 (57%) were female. The 5-year OS was 96.9% in the TL group and 96.8% in the TT + RAI group (hazard ratio [HR], 0.2; 95% CI, 0.03-1.58). The 5-year DSS was 96.7% in the TL group and 100% in the TT +RAI group. The 5-year RFS was 89.8% in the TL group and 88.9% in the TT + RAI group (HR, 1.48; 95% CI, 0.39-5.58). The survival rates did not change between 5 and 10 years.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that a select group of patients with N1b PTC treated with TL had no important difference in survival and recurrence outcomes compared with patients treated with TT + RAI. Therefore, TL is an effective and safe treatment option in carefully selected and appropriately counselled patients with N1b PTC with unilateral tumors and low-volume regional lymph node metastases without clinical extranodal extension.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoto.2025.4653","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:35Z","timestamp":1766073635000},"page":"208","source":"Crossref","is-referenced-by-count":1,"title":["Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma"],"prefix":"10.1001","volume":"152","author":[{"given":"Daniel W.","family":"Scholfield","sequence":"first","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian A.","family":"Boe","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Eagan","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Levyn","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fergal","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Michael","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok R.","family":"Shaha","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Cracchiolo","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Wong","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehal G.","family":"Patel","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Ganly","sequence":"additional","affiliation":[{"name":"Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"ooi250081r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"8","key":"ooi250081r2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology.","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"ooi250081r3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1507\/endocrj.EJ24-0644","article-title":"The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.","volume":"72","author":"Sugitani","year":"2025","journal-title":"Endocr J"},{"issue":"1","key":"ooi250081r4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/jamasurg.2022.5781","article-title":"Comparison of lobectomy vs total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis.","volume":"158","author":"Xu","year":"2023","journal-title":"JAMA Surg"},{"issue":"4","key":"ooi250081r5","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1245\/s10434-024-16643-5","article-title":"Feasibility of lobectomy in selected patients with unilateral N1b papillary thyroid cancer.","volume":"32","author":"Li","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"ooi250081r6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.4158\/EP-2020-0125","article-title":"Unilateral Tnm T1 And T2 papillary thyroid carcinoma with lateral cervical lymph node metastasis: total thyroidectomy or lobectomy?","volume":"26","author":"Wang","year":"2020","journal-title":"Endocr Pract"},{"issue":"2","key":"ooi250081r7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1001\/jamaoto.2024.3860","article-title":"Lobectomy vs total thyroidectomy with ipsilateral lateral neck dissection for N1b intermediate-risk papillary thyroid carcinoma.","volume":"151","author":"Saito","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"ooi250081r8","doi-asserted-by":"publisher","first-page":"6343","DOI":"10.1097\/JS9.0000000000002673","article-title":"Comparison of total thyroidectomy and lobectomy for intermediate-risk papillary thyroid carcinoma with lateral lymph node metastasis: a systematic review and meta-analysis.","volume":"111","author":"Li","year":"2025","journal-title":"Int J Surg"},{"issue":"12","key":"ooi250081r9","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1245\/s10434-014-3846-8","article-title":"Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons.","volume":"21","author":"Hauch","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"ooi250081r10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/thy.2023.0328","article-title":"Health-related quality of life in patients with low-risk differentiated thyroid cancer: a systematic review examining the extent of thyroidectomy.","volume":"34","author":"Bach","year":"2024","journal-title":"Thyroid"},{"issue":"3","key":"ooi250081r11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/jamasurg.2021.6442","article-title":"Association of total thyroidectomy or thyroid lobectomy with the quality of life in patients with differentiated thyroid cancer with low to intermediate risk of recurrence.","volume":"157","author":"Chen","year":"2022","journal-title":"JAMA Surg"},{"issue":"3","key":"ooi250081r12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1001\/jamaoto.2018.3870","article-title":"Health-related quality of life after diagnosis and treatment of differentiated thyroid cancer and association with type of surgical treatment.","volume":"145","author":"Nickel","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"17","key":"ooi250081r13","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3390\/cancers16173096","article-title":"Decision variables for the use of radioactive iodine in patients with thyroid cancer at intermediate risk of recurrence.","volume":"16","author":"Newman","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ooi250081r14","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/hed.26417","article-title":"Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology.","volume":"42","author":"Singer","year":"2020","journal-title":"Head Neck"},{"issue":"18","key":"ooi250081r15","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1200\/JCO.2017.75.0232","article-title":"Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer.","volume":"36","author":"Molenaar","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"ooi250081r16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/s12885-021-08292-8","article-title":"Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.","volume":"21","author":"Mei","year":"2021","journal-title":"BMC Cancer"},{"issue":"13","key":"ooi250081r17","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.21.01841","article-title":"Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies.","volume":"40","author":"Pasqual","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"ooi250081r18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3803\/EnM.2020.35.1.115","article-title":"Quality of life in patients with papillary thyroid microcarcinoma according to treatment: total thyroidectomy with or without radioactive iodine ablation.","volume":"35","author":"Ahn","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"ooi250081r19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/ERC-15-0572","article-title":"Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.","volume":"23","author":"Kim","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"ooi250081r20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.surg.2012.08.034","article-title":"Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer\u2014is there a need for radioactive iodine therapy?","volume":"152","author":"Ibrahimpasic","year":"2012","journal-title":"Surgery"},{"issue":"12","key":"ooi250081r21","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"ooi250081r22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.119.227652","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer.","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"ooi250081r23","doi-asserted-by":"publisher","first-page":"16955","DOI":"10.1038\/s41598-017-17176-6","article-title":"Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer.","volume":"7","author":"Kim","year":"2017","journal-title":"Sci Rep"}],"container-title":["JAMA Otolaryngology\u2013Head & Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2842513\/jamaotolaryngology_scholfield_2025_oi_250081_1770606653.54271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:01:09Z","timestamp":1770912069000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2842513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2025.4653","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}